CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Market dynamics
3.4.1.Drivers
3.4.2.Restraints
3.4.3.Opportunities
3.5.COVID-19 Impact Analysis on the market
3.6.Value Chain Analysis
3.7.Key Regulation Analysis
3.8.Patent Landscape
3.9.Regulatory Guidelines
3.10.Market Share Analysis
CHAPTER 4: COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2. Dog
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3. Cat
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
4.4. Horse
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market share analysis by country
CHAPTER 5: COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE
5.1 Overview
5.1.1 Market size and forecast
5.2. Osteoarthritis
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3. Rheumatoid Arthritis
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
CHAPTER 6: COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT
6.1 Overview
6.1.1 Market size and forecast
6.2. Exercise
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market share analysis by country
6.3. Medical
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market share analysis by country
6.4. Others
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market share analysis by country
CHAPTER 7: COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL
7.1 Overview
7.1.1 Market size and forecast
7.2. Online Store
7.2.1 Key market trends, growth factors and opportunities
7.2.2 Market size and forecast, by region
7.2.3 Market share analysis by country
7.3. Pet Supply Store
7.3.1 Key market trends, growth factors and opportunities
7.3.2 Market size and forecast, by region
7.3.3 Market share analysis by country
7.4. Veterinary Hospitals and Clinics
7.4.1 Key market trends, growth factors and opportunities
7.4.2 Market size and forecast, by region
7.4.3 Market share analysis by country
7.5. Others
7.5.1 Key market trends, growth factors and opportunities
7.5.2 Market size and forecast, by region
7.5.3 Market share analysis by country
CHAPTER 8: COMPANION ANIMAL ARTHRITIS MARKET, BY REGION
8.1 Overview
8.1.1 Market size and forecast
8.2 North America
8.2.1 Key trends and opportunities
8.2.2 North America Market size and forecast, by Companion Type
8.2.3 North America Market size and forecast, by Arthritis Type
8.2.4 North America Market size and forecast, by Treatment
8.2.5 North America Market size and forecast, by Distribution Channel
8.2.6 North America Market size and forecast, by country
8.2.6.1 U.S.
8.2.6.1.1 Key market trends, growth factors and opportunities
8.2.6.1.2 Market size and forecast, by Companion Type
8.2.6.1.3 Market size and forecast, by Arthritis Type
8.2.6.1.4 Market size and forecast, by Treatment
8.2.6.1.5 Market size and forecast, by Distribution Channel
8.2.6.2 Canada
8.2.6.2.1 Key market trends, growth factors and opportunities
8.2.6.2.2 Market size and forecast, by Companion Type
8.2.6.2.3 Market size and forecast, by Arthritis Type
8.2.6.2.4 Market size and forecast, by Treatment
8.2.6.2.5 Market size and forecast, by Distribution Channel
8.2.6.3 Mexico
8.2.6.3.1 Key market trends, growth factors and opportunities
8.2.6.3.2 Market size and forecast, by Companion Type
8.2.6.3.3 Market size and forecast, by Arthritis Type
8.2.6.3.4 Market size and forecast, by Treatment
8.2.6.3.5 Market size and forecast, by Distribution Channel
8.3 Europe
8.3.1 Key trends and opportunities
8.3.2 Europe Market size and forecast, by Companion Type
8.3.3 Europe Market size and forecast, by Arthritis Type
8.3.4 Europe Market size and forecast, by Treatment
8.3.5 Europe Market size and forecast, by Distribution Channel
8.3.6 Europe Market size and forecast, by country
8.3.6.1 Germany
8.3.6.1.1 Key market trends, growth factors and opportunities
8.3.6.1.2 Market size and forecast, by Companion Type
8.3.6.1.3 Market size and forecast, by Arthritis Type
8.3.6.1.4 Market size and forecast, by Treatment
8.3.6.1.5 Market size and forecast, by Distribution Channel
8.3.6.2 UK
8.3.6.2.1 Key market trends, growth factors and opportunities
8.3.6.2.2 Market size and forecast, by Companion Type
8.3.6.2.3 Market size and forecast, by Arthritis Type
8.3.6.2.4 Market size and forecast, by Treatment
8.3.6.2.5 Market size and forecast, by Distribution Channel
8.3.6.3 France
8.3.6.3.1 Key market trends, growth factors and opportunities
8.3.6.3.2 Market size and forecast, by Companion Type
8.3.6.3.3 Market size and forecast, by Arthritis Type
8.3.6.3.4 Market size and forecast, by Treatment
8.3.6.3.5 Market size and forecast, by Distribution Channel
8.3.6.4 Spain
8.3.6.4.1 Key market trends, growth factors and opportunities
8.3.6.4.2 Market size and forecast, by Companion Type
8.3.6.4.3 Market size and forecast, by Arthritis Type
8.3.6.4.4 Market size and forecast, by Treatment
8.3.6.4.5 Market size and forecast, by Distribution Channel
8.3.6.5 Italy
8.3.6.5.1 Key market trends, growth factors and opportunities
8.3.6.5.2 Market size and forecast, by Companion Type
8.3.6.5.3 Market size and forecast, by Arthritis Type
8.3.6.5.4 Market size and forecast, by Treatment
8.3.6.5.5 Market size and forecast, by Distribution Channel
8.3.6.6 Rest of Europe
8.3.6.6.1 Key market trends, growth factors and opportunities
8.3.6.6.2 Market size and forecast, by Companion Type
8.3.6.6.3 Market size and forecast, by Arthritis Type
8.3.6.6.4 Market size and forecast, by Treatment
8.3.6.6.5 Market size and forecast, by Distribution Channel
8.4 Asia-Pacific
8.4.1 Key trends and opportunities
8.4.2 Asia-Pacific Market size and forecast, by Companion Type
8.4.3 Asia-Pacific Market size and forecast, by Arthritis Type
8.4.4 Asia-Pacific Market size and forecast, by Treatment
8.4.5 Asia-Pacific Market size and forecast, by Distribution Channel
8.4.6 Asia-Pacific Market size and forecast, by country
8.4.6.1 China
8.4.6.1.1 Key market trends, growth factors and opportunities
8.4.6.1.2 Market size and forecast, by Companion Type
8.4.6.1.3 Market size and forecast, by Arthritis Type
8.4.6.1.4 Market size and forecast, by Treatment
8.4.6.1.5 Market size and forecast, by Distribution Channel
8.4.6.2 Japan
8.4.6.2.1 Key market trends, growth factors and opportunities
8.4.6.2.2 Market size and forecast, by Companion Type
8.4.6.2.3 Market size and forecast, by Arthritis Type
8.4.6.2.4 Market size and forecast, by Treatment
8.4.6.2.5 Market size and forecast, by Distribution Channel
8.4.6.3 India
8.4.6.3.1 Key market trends, growth factors and opportunities
8.4.6.3.2 Market size and forecast, by Companion Type
8.4.6.3.3 Market size and forecast, by Arthritis Type
8.4.6.3.4 Market size and forecast, by Treatment
8.4.6.3.5 Market size and forecast, by Distribution Channel
8.4.6.4 South Korea
8.4.6.4.1 Key market trends, growth factors and opportunities
8.4.6.4.2 Market size and forecast, by Companion Type
8.4.6.4.3 Market size and forecast, by Arthritis Type
8.4.6.4.4 Market size and forecast, by Treatment
8.4.6.4.5 Market size and forecast, by Distribution Channel
8.4.6.5 Australia
8.4.6.5.1 Key market trends, growth factors and opportunities
8.4.6.5.2 Market size and forecast, by Companion Type
8.4.6.5.3 Market size and forecast, by Arthritis Type
8.4.6.5.4 Market size and forecast, by Treatment
8.4.6.5.5 Market size and forecast, by Distribution Channel
8.4.6.6 Rest of Asia-Pacific
8.4.6.6.1 Key market trends, growth factors and opportunities
8.4.6.6.2 Market size and forecast, by Companion Type
8.4.6.6.3 Market size and forecast, by Arthritis Type
8.4.6.6.4 Market size and forecast, by Treatment
8.4.6.6.5 Market size and forecast, by Distribution Channel
8.5 LAMEA
8.5.1 Key trends and opportunities
8.5.2 LAMEA Market size and forecast, by Companion Type
8.5.3 LAMEA Market size and forecast, by Arthritis Type
8.5.4 LAMEA Market size and forecast, by Treatment
8.5.5 LAMEA Market size and forecast, by Distribution Channel
8.5.6 LAMEA Market size and forecast, by country
8.5.6.1 Brazil
8.5.6.1.1 Key market trends, growth factors and opportunities
8.5.6.1.2 Market size and forecast, by Companion Type
8.5.6.1.3 Market size and forecast, by Arthritis Type
8.5.6.1.4 Market size and forecast, by Treatment
8.5.6.1.5 Market size and forecast, by Distribution Channel
8.5.6.2 Saudi Arabia
8.5.6.2.1 Key market trends, growth factors and opportunities
8.5.6.2.2 Market size and forecast, by Companion Type
8.5.6.2.3 Market size and forecast, by Arthritis Type
8.5.6.2.4 Market size and forecast, by Treatment
8.5.6.2.5 Market size and forecast, by Distribution Channel
8.5.6.3 United Arab Emirates
8.5.6.3.1 Key market trends, growth factors and opportunities
8.5.6.3.2 Market size and forecast, by Companion Type
8.5.6.3.3 Market size and forecast, by Arthritis Type
8.5.6.3.4 Market size and forecast, by Treatment
8.5.6.3.5 Market size and forecast, by Distribution Channel
8.5.6.4 South Africa
8.5.6.4.1 Key market trends, growth factors and opportunities
8.5.6.4.2 Market size and forecast, by Companion Type
8.5.6.4.3 Market size and forecast, by Arthritis Type
8.5.6.4.4 Market size and forecast, by Treatment
8.5.6.4.5 Market size and forecast, by Distribution Channel
8.5.6.5 Rest of LAMEA
8.5.6.5.1 Key market trends, growth factors and opportunities
8.5.6.5.2 Market size and forecast, by Companion Type
8.5.6.5.3 Market size and forecast, by Arthritis Type
8.5.6.5.4 Market size and forecast, by Treatment
8.5.6.5.5 Market size and forecast, by Distribution Channel
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2021
CHAPTER 10: COMPANY PROFILES
10.1 Covetrus, Inc.
10.1.1 Company overview
10.1.2 Key Executives
10.1.3 Company snapshot
10.1.4 Operating business segments
10.1.5 Product portfolio
10.1.6 Business performance
10.1.7 Key strategic moves and developments
10.2 Zoetis
10.2.1 Company overview
10.2.2 Key Executives
10.2.3 Company snapshot
10.2.4 Operating business segments
10.2.5 Product portfolio
10.2.6 Business performance
10.2.7 Key strategic moves and developments
10.3 Elanco
10.3.1 Company overview
10.3.2 Key Executives
10.3.3 Company snapshot
10.3.4 Operating business segments
10.3.5 Product portfolio
10.3.6 Business performance
10.3.7 Key strategic moves and developments
10.4 Virbac
10.4.1 Company overview
10.4.2 Key Executives
10.4.3 Company snapshot
10.4.4 Operating business segments
10.4.5 Product portfolio
10.4.6 Business performance
10.4.7 Key strategic moves and developments
10.5 Dechra Pharmaceuticals plc
10.5.1 Company overview
10.5.2 Key Executives
10.5.3 Company snapshot
10.5.4 Operating business segments
10.5.5 Product portfolio
10.5.6 Business performance
10.5.7 Key strategic moves and developments
10.6 Vetoquinol Animal Health Pvt Ltd
10.6.1 Company overview
10.6.2 Key Executives
10.6.3 Company snapshot
10.6.4 Operating business segments
10.6.5 Product portfolio
10.6.6 Business performance
10.6.7 Key strategic moves and developments
10.7 Phibro Animal Health Corp
10.7.1 Company overview
10.7.2 Key Executives
10.7.3 Company snapshot
10.7.4 Operating business segments
10.7.5 Product portfolio
10.7.6 Business performance
10.7.7 Key strategic moves and developments
10.8 Boehringer Ingelheim GmbH
10.8.1 Company overview
10.8.2 Key Executives
10.8.3 Company snapshot
10.8.4 Operating business segments
10.8.5 Product portfolio
10.8.6 Business performance
10.8.7 Key strategic moves and developments
10.9 Bayer AG
10.9.1 Company overview
10.9.2 Key Executives
10.9.3 Company snapshot
10.9.4 Operating business segments
10.9.5 Product portfolio
10.9.6 Business performance
10.9.7 Key strategic moves and developments
10.10 Ceva Sante Animale
10.10.1 Company overview
10.10.2 Key Executives
10.10.3 Company snapshot
10.10.4 Operating business segments
10.10.5 Product portfolio
10.10.6 Business performance
10.10.7 Key strategic moves and developments
TABLE 1. GLOBAL COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 2. COMPANION ANIMAL ARTHRITIS MARKET FOR DOG, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 3. COMPANION ANIMAL ARTHRITIS MARKET FOR CAT, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 4. COMPANION ANIMAL ARTHRITIS MARKET FOR HORSE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 5. GLOBAL COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 6. COMPANION ANIMAL ARTHRITIS MARKET FOR OSTEOARTHRITIS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 7. COMPANION ANIMAL ARTHRITIS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 8. GLOBAL COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 9. COMPANION ANIMAL ARTHRITIS MARKET FOR EXERCISE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 10. COMPANION ANIMAL ARTHRITIS MARKET FOR MEDICAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 11. COMPANION ANIMAL ARTHRITIS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 12. GLOBAL COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 13. COMPANION ANIMAL ARTHRITIS MARKET FOR ONLINE STORE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 14. COMPANION ANIMAL ARTHRITIS MARKET FOR PET SUPPLY STORE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 15. COMPANION ANIMAL ARTHRITIS MARKET FOR VETERINARY HOSPITALS AND CLINICS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 16. COMPANION ANIMAL ARTHRITIS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 17. COMPANION ANIMAL ARTHRITIS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 18. NORTH AMERICA COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 19. NORTH AMERICA COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 20. NORTH AMERICA COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 21. NORTH AMERICA COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 22. NORTH AMERICA COMPANION ANIMAL ARTHRITIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 23. U.S. COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 24. U.S. COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 25. U.S. COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 26. U.S. COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 27. CANADA COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 28. CANADA COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 29. CANADA COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 30. CANADA COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 31. MEXICO COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 32. MEXICO COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 33. MEXICO COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 34. MEXICO COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 35. EUROPE COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 36. EUROPE COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 37. EUROPE COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 38. EUROPE COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 39. EUROPE COMPANION ANIMAL ARTHRITIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 40. GERMANY COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 41. GERMANY COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 42. GERMANY COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 43. GERMANY COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 44. UK COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 45. UK COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 46. UK COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 47. UK COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 48. FRANCE COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 49. FRANCE COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 50. FRANCE COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 51. FRANCE COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 52. SPAIN COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 53. SPAIN COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 54. SPAIN COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 55. SPAIN COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 56. ITALY COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 57. ITALY COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 58. ITALY COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 59. ITALY COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 60. REST OF EUROPE COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 61. REST OF EUROPE COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 62. REST OF EUROPE COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 63. REST OF EUROPE COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 64. ASIA-PACIFIC COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 65. ASIA-PACIFIC COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 66. ASIA-PACIFIC COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 67. ASIA-PACIFIC COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 68. ASIA-PACIFIC COMPANION ANIMAL ARTHRITIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 69. CHINA COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 70. CHINA COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 71. CHINA COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 72. CHINA COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 73. JAPAN COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 74. JAPAN COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 75. JAPAN COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 76. JAPAN COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 77. INDIA COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 78. INDIA COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 79. INDIA COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 80. INDIA COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 81. SOUTH KOREA COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 82. SOUTH KOREA COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 83. SOUTH KOREA COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 84. SOUTH KOREA COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 85. AUSTRALIA COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 86. AUSTRALIA COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 87. AUSTRALIA COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 88. AUSTRALIA COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 89. REST OF ASIA-PACIFIC COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 90. REST OF ASIA-PACIFIC COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 91. REST OF ASIA-PACIFIC COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 92. REST OF ASIA-PACIFIC COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 93. LAMEA COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 94. LAMEA COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 95. LAMEA COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 96. LAMEA COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 97. LAMEA COMPANION ANIMAL ARTHRITIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 98. BRAZIL COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 99. BRAZIL COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 100. BRAZIL COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 101. BRAZIL COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 102. SAUDI ARABIA COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 103. SAUDI ARABIA COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 104. SAUDI ARABIA COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 105. SAUDI ARABIA COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 106. UNITED ARAB EMIRATES COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 107. UNITED ARAB EMIRATES COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 108. UNITED ARAB EMIRATES COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 109. UNITED ARAB EMIRATES COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 110. SOUTH AFRICA COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 111. SOUTH AFRICA COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 112. SOUTH AFRICA COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 113. SOUTH AFRICA COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 114. REST OF LAMEA COMPANION ANIMAL ARTHRITIS MARKET, BY COMPANION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 115. REST OF LAMEA COMPANION ANIMAL ARTHRITIS MARKET, BY ARTHRITIS TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 116. REST OF LAMEA COMPANION ANIMAL ARTHRITIS MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 117. REST OF LAMEA COMPANION ANIMAL ARTHRITIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 118. COVETRUS, INC.: KEY EXECUTIVES
TABLE 119. COVETRUS, INC.: COMPANY SNAPSHOT
TABLE 120. COVETRUS, INC.: OPERATING SEGMENTS
TABLE 121. COVETRUS, INC.: PRODUCT PORTFOLIO
TABLE 122. COVETRUS, INC.: NET SALES
TABLE 123. COVETRUS, INC.: KEY STRATERGIES
TABLE 124. ZOETIS: KEY EXECUTIVES
TABLE 125. ZOETIS: COMPANY SNAPSHOT
TABLE 126. ZOETIS: OPERATING SEGMENTS
TABLE 127. ZOETIS: PRODUCT PORTFOLIO
TABLE 128. ZOETIS: NET SALES
TABLE 129. ZOETIS: KEY STRATERGIES
TABLE 130. ELANCO: KEY EXECUTIVES
TABLE 131. ELANCO: COMPANY SNAPSHOT
TABLE 132. ELANCO: OPERATING SEGMENTS
TABLE 133. ELANCO: PRODUCT PORTFOLIO
TABLE 134. ELANCO: NET SALES
TABLE 135. ELANCO: KEY STRATERGIES
TABLE 136. VIRBAC: KEY EXECUTIVES
TABLE 137. VIRBAC: COMPANY SNAPSHOT
TABLE 138. VIRBAC: OPERATING SEGMENTS
TABLE 139. VIRBAC: PRODUCT PORTFOLIO
TABLE 140. VIRBAC: NET SALES
TABLE 141. VIRBAC: KEY STRATERGIES
TABLE 142. DECHRA PHARMACEUTICALS PLC: KEY EXECUTIVES
TABLE 143. DECHRA PHARMACEUTICALS PLC: COMPANY SNAPSHOT
TABLE 144. DECHRA PHARMACEUTICALS PLC: OPERATING SEGMENTS
TABLE 145. DECHRA PHARMACEUTICALS PLC: PRODUCT PORTFOLIO
TABLE 146. DECHRA PHARMACEUTICALS PLC: NET SALES
TABLE 147. DECHRA PHARMACEUTICALS PLC: KEY STRATERGIES
TABLE 148. VETOQUINOL ANIMAL HEALTH PVT LTD: KEY EXECUTIVES
TABLE 149. VETOQUINOL ANIMAL HEALTH PVT LTD: COMPANY SNAPSHOT
TABLE 150. VETOQUINOL ANIMAL HEALTH PVT LTD: OPERATING SEGMENTS
TABLE 151. VETOQUINOL ANIMAL HEALTH PVT LTD: PRODUCT PORTFOLIO
TABLE 152. VETOQUINOL ANIMAL HEALTH PVT LTD: NET SALES
TABLE 153. VETOQUINOL ANIMAL HEALTH PVT LTD: KEY STRATERGIES
TABLE 154. PHIBRO ANIMAL HEALTH CORP: KEY EXECUTIVES
TABLE 155. PHIBRO ANIMAL HEALTH CORP: COMPANY SNAPSHOT
TABLE 156. PHIBRO ANIMAL HEALTH CORP: OPERATING SEGMENTS
TABLE 157. PHIBRO ANIMAL HEALTH CORP: PRODUCT PORTFOLIO
TABLE 158. PHIBRO ANIMAL HEALTH CORP: NET SALES
TABLE 159. PHIBRO ANIMAL HEALTH CORP: KEY STRATERGIES
TABLE 160. BOEHRINGER INGELHEIM GMBH: KEY EXECUTIVES
TABLE 161. BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT
TABLE 162. BOEHRINGER INGELHEIM GMBH: OPERATING SEGMENTS
TABLE 163. BOEHRINGER INGELHEIM GMBH: PRODUCT PORTFOLIO
TABLE 164. BOEHRINGER INGELHEIM GMBH: NET SALES
TABLE 165. BOEHRINGER INGELHEIM GMBH: KEY STRATERGIES
TABLE 166. BAYER AG: KEY EXECUTIVES
TABLE 167. BAYER AG: COMPANY SNAPSHOT
TABLE 168. BAYER AG: OPERATING SEGMENTS
TABLE 169. BAYER AG: PRODUCT PORTFOLIO
TABLE 170. BAYER AG: NET SALES
TABLE 171. BAYER AG: KEY STRATERGIES
TABLE 172. CEVA SANTE ANIMALE: KEY EXECUTIVES
TABLE 173. CEVA SANTE ANIMALE: COMPANY SNAPSHOT
TABLE 174. CEVA SANTE ANIMALE: OPERATING SEGMENTS
TABLE 175. CEVA SANTE ANIMALE: PRODUCT PORTFOLIO
TABLE 176. CEVA SANTE ANIMALE: NET SALES
TABLE 177. CEVA SANTE ANIMALE: KEY STRATERGIES
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
